ID: ALA501319

Max Phase: Preclinical

Molecular Formula: C34H38N4O3

Molecular Weight: 550.70

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC(=O)CCCCC[C@H](NC(=O)Cc1c(C)[nH]c2ccc(OC)cc12)c1ncc(-c2ccc3ccccc3c2)[nH]1

Standard InChI:  InChI=1S/C34H38N4O3/c1-4-26(39)12-6-5-7-13-31(34-35-21-32(38-34)25-15-14-23-10-8-9-11-24(23)18-25)37-33(40)20-28-22(2)36-30-17-16-27(41-3)19-29(28)30/h8-11,14-19,21,31,36H,4-7,12-13,20H2,1-3H3,(H,35,38)(H,37,40)/t31-/m0/s1

Standard InChI Key:  ISRLBVVRURBWCS-HKBQPEDESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 550.70

Molecular Weight (Monoisotopic): 550.2944

AlogP: 7.36

#Rotatable Bonds: 13

Polar Surface Area: 99.87

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.44

CX Basic pKa: 5.78

CX LogP: 5.98

CX LogD: 5.97

Aromatic Rings: 5

Heavy Atoms: 41

QED Weighted: 0.13

Np Likeness Score: -0.43

References

1. Attenni B, Ontoria JM, Cruz JC, Rowley M, Schultz-Fademrecht C, Steinkühler C, Jones P..  (2009)  Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.,  19  (11): [PMID:19410459] [10.1016/j.bmcl.2009.04.011]

2. Bresciani A, Ontoria JM, Biancofiore I, Cellucci A, Ciammaichella A, Di Marco A, Ferrigno F, Francone A, Malancona S, Monteagudo E, Nizi E, Pace P, Ponzi S, Rossetti I, Veneziano M, Summa V, Harper S..  (2019)  Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.,  10  (4): [PMID:30996783] [10.1021/acsmedchemlett.8b00517]

Source

Source(1):

• Scientific Literature